Telomerase (TERT) is a major oncogene responsible for primary brain tumours, and its promoter mutation is found in approximately 80% of primary GBM cases, making TERT-derived peptides an ideal target for GBM neoantigen vaccines. The gene discussed is TERT; the disease is glioblastoma.